Anja Ten Brinke, David W. C. Dekkers, Silla M. Notten, Miriam L. Karsten, Els R. de Groot, Lucien A. Aarden
European Cytokine Network, Vol.16, No.2, pp. 144-151, 2005
Abstract 4-hydroxy-oxyphenbutazone (4OH-OPB), is currently in phase II trials for its immunosuppressive
effect in patients with rheumatoid arthritis. 4OH-OPB and other compounds related to phenylbutazone were
tested for their effect on in vitro cytokine production by monocytes and lymphocytes present in peripheral
mononuclear cells (PBMC) or whole blood (WB) cultures, and compared against phenylbutazone and oxyphenbutazone,
two known anti-inflammatory drugs. In PBMC cultures, 4OH-OPB was by far the most potent
inhibitor, and both monokines and Th1 and Th2 lymphokines were efficiently inhibited at low concentrations. In
WB cultures, 4OH-OPB was less effective than in PBMC cultures,… More >